S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:VTRS

Viatris (VTRS) Competitors

$9.38
-0.14 (-1.47%)
(As of 06/9/2023 ET)
Compare
Today's Range
$9.34
$9.49
50-Day Range
$9.02
$9.92
52-Week Range
$8.42
$12.40
Volume
6.55 million shs
Average Volume
9.41 million shs
Market Capitalization
$11.25 billion
P/E Ratio
5.97
Dividend Yield
5.12%
Price Target
$12.67

VTRS vs. LEGN, SRPT, APLS, UTHR, RXDX, RDY, KRTX, JAZZ, TEVA, and ROIV

Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Apellis Pharmaceuticals (APLS), United Therapeutics (UTHR), Prometheus Biosciences (RXDX), Dr. Reddy's Laboratories (RDY), Karuna Therapeutics (KRTX), Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.

Viatris vs.

Viatris (NASDAQ:VTRS) and Legend Biotech (NASDAQ:LEGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.

In the previous week, Legend Biotech had 7 more articles in the media than Viatris. MarketBeat recorded 11 mentions for Legend Biotech and 4 mentions for Viatris. Viatris' average media sentiment score of 0.82 beat Legend Biotech's score of 0.27 indicating that Viatris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viatris
1 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Viatris has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.

Viatris has a net margin of 12.05% compared to Legend Biotech's net margin of 0.00%. Viatris' return on equity of 19.19% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Viatris 12.05% 19.19% 7.80%
Legend Biotech N/A N/A N/A

Legend Biotech received 18 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 57.35% of users gave Legend Biotech an outperform vote while only 41.18% of users gave Viatris an outperform vote.

CompanyUnderperformOutperform
ViatrisOutperform Votes
21
41.18%
Underperform Votes
30
58.82%
Legend BiotechOutperform Votes
39
57.35%
Underperform Votes
29
42.65%

Viatris has higher revenue and earnings than Legend Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viatris$16.26 billion0.70$2.08 billion$1.576.02
Legend Biotech$117 million97.17-$446.35 millionN/AN/A

74.7% of Viatris shares are owned by institutional investors. Comparatively, 38.9% of Legend Biotech shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viatris presently has a consensus target price of $12.67, suggesting a potential upside of 34.18%. Legend Biotech has a consensus target price of $77.90, suggesting a potential upside of 13.05%. Given Viatris' higher possible upside, equities analysts clearly believe Viatris is more favorable than Legend Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatris
0 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.14
Legend Biotech
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.87

Summary

Viatris beats Legend Biotech on 10 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTRS vs. The Competition

MetricViatrisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$11.33B$5.88B$4.57B$6.33B
Dividend Yield4.94%2.59%2.37%6.18%
P/E Ratio6.024.2792.8311.89
Price / Sales0.70331.323,481.0089.33
Price / Cash1.6620.9591.53113.49
Price / Book0.544.824.715.34
Net Income$2.08B$190.18M$117.86M$192.92M
7 Day Performance1.29%1.43%1.61%2.19%
1 Month Performance-2.98%1.91%2.20%5.83%
1 Year Performance-18.67%18.47%9.28%3.73%

Viatris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LEGN
Legend Biotech
1.7194 of 5 stars
$68.06
+4.2%
$77.90
+14.5%
+39.1%$11.23B$117M0.001,390Analyst Report
Analyst Revision
SRPT
Sarepta Therapeutics
2.8634 of 5 stars
$128.60
+1.9%
$168.76
+31.2%
+74.2%$11.98B$933.01M-10.131,162
APLS
Apellis Pharmaceuticals
1.5135 of 5 stars
$91.22
+1.6%
$90.93
-0.3%
+105.6%$10.62B$75.42M-14.55476Insider Selling
News Coverage
UTHR
United Therapeutics
3.1947 of 5 stars
$220.25
+0.6%
$294.67
+33.8%
-1.0%$10.32B$1.94B14.83965Positive News
RXDX
Prometheus Biosciences
1.5362 of 5 stars
$198.85
+0.0%
$153.36
-22.9%
+586.1%$9.51B$6.81M-56.4972Positive News
RDY
Dr. Reddy's Laboratories
1.8628 of 5 stars
$56.74
+0.6%
$70.00
+23.4%
+5.4%$9.45B$245.88B17.0424,795
KRTX
Karuna Therapeutics
1.6369 of 5 stars
$236.30
+0.9%
$277.13
+17.3%
+110.5%$8.85B$10.64M-24.69118
JAZZ
Jazz Pharmaceuticals
2.622 of 5 stars
$128.91
-0.6%
$200.75
+55.7%
-15.8%$8.25B$3.74B-50.752,800
TEVA
Teva Pharmaceutical Industries
2.0526 of 5 stars
$7.22
+0.1%
$10.67
+47.7%
-16.0%$8.09B$14.93B-5.0136,826
ROIV
Roivant Sciences
1.8064 of 5 stars
$9.75
+3.5%
$12.80
+31.3%
+137.7%$7.39B$55.29M-5.48620Analyst Report
News Coverage

Related Companies and Tools

This page (NASDAQ:VTRS) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -